Mycovia Pharmaceuticals announces U.S. FDA acceptance and priority review of new drug application for oteseconazole for the treatment of recurrent vulvovaginal candidiasis

Mycovia Pharmaceuticals

28 July 2021 - Six month priority review granted for oteseconazole with PDUFA target action date set for 27 January 2022.

Mycovia today announced the U.S. FDA has accepted for review its new drug application for oteseconazole, an oral anti-fungal product for the treatment of recurrent vulvovaginal candidiasis.

Read Mycovia Pharmaceuticals press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Dossier